Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Engineering × NET × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 37 Everolimus 31 Magnetic Resonance Spectroscopy 15 lanreotide 12 gallium Ga 68 dotatate 12 Temozolomide 11 Octreotide 11 Nivolumab 10 Capecitabine 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 9 pembrolizumab 8 cabozantinib 7 Sunitinib 7 Specimen Handling 7 Positron Emission Tomography Computed Tomography 7 3-Iodobenzylguanidine 7 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 amino-acid, glucose, and electrolyte solution 5 Fluorodeoxyglucose F18 5 telotristat ethyl 4 pasireotide 4 olaparib 4 copper dotatate CU-64 4 avelumab 4 Ipilimumab 4 Injections 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡